Akelos, Inc.
Biotechnology company · New York, United States
Akelos, Inc. is a biotechnology company headquartered in New York, United States. Its earliest recorded incorporation is in 2018. It has received 1 US government small-business research award (SBIR/STTR) from health agencies, $698,818 in total, most recently in 2022. It has reported private securities offerings to the US SEC, most recently $1.5 million sold in a notice filed in 2026.
Akelos at a glance
What does Akelos do?
US government research funding
1 SBIR/STTR small-business research award from US health agencies, $698,818 in total (2022). NIH funding came from the National Institute of Neurological Disorders and Stroke.
Private fundraising reported to the SEC
4 Form D notices; the most recent reported $1.5 million sold (2026).
Frequently asked questions about Akelos
Where is Akelos headquartered?
Akelos, Inc. is headquartered in New York, United States.
What does Akelos do?
Akelos, Inc. is a biotechnology company.
When was Akelos founded?
The earliest incorporation on record for Akelos, Inc. is in 2018, according to public company registers.
Similar companies
- Lexeo Therapeutics, Inc.New York City, New York, United States
- MiNK Therapeutics, Inc.New York City, New York, United States
- IN8BIO, Inc.New York City, New York, United States
- Anavex Life Sciences Corp.New York City, New York, United States
- Brainstorm Cell Therapeutics Inc.New York City, New York, United States
- Bioincept LLCNew York City, New York, United States
- Protara Therapeutics, Inc.New York City, New York, United States
- Ancilia Biosciences, Inc.New York City, New York, United States
Need a CRO or CDMO for your next study?
Compare transparent quotes from research and manufacturing partners, then contract once. Free for buyers.
Compare quotesLast updated 2026-09-25. Data licences